Design and patients
The LAPOP study is a randomized controlled non-blinded parallel assignment single-center superiority trial on the effectiveness of LDP versus ODP in the settings of lesions in the pancreatic body or tail regardless of suspicion of malignancy. Patients fulfilling inclusions criteria and not meeting any of the exclusion criteria will be randomized in a 1:1 manner to LDP or ODP.
All patients with tumors in the body and the tail of the pancreas in the South-East health district in Sweden are presented on the MDB (Multidisciplinary board) at the study site (Linköping University Hospital). Here eligibility screening is performed.
Sample size
The sample size considerations are based on the primary endpoint hospital stay in an intention to treat manner. One sided power calculation is used as none of the previous publications indicates inferiority for LDP. Assumed mean hospital stay is 5 and 7.5 days for laparoscopic respective open operations. The standard deviation is 3,5 and with type I error = 0.05 and a 0.8 power 25 patients are needed in each group.
Due to possible drop-outs 30 patients will be included in each group.
Inclusion and exclusion criteria
The inclusion criteria for the LAPOP study are set as follows:
· Patients with lesion in the body or tail of the pancreas demanding surgery (indication set by multidisciplinary conference).
· Operable patient (as the local preoperatively evaluation dictates).
· Possibility to achieve R0-resection without resection of additional organs (besides the spleen)
· Patients with performance status 0-2 according to WHO scale.
· Written informed consent.
· Age > 18 years
The following exclusion criteria apply:
· Pregnancy and/or lactation.
· Patients being unable to comply with the protocol for reasons of language or cognitive function.
· Preoperatively defined need to resect other organs than pancreas and spleen.
· Preoperatively defined division line of pancreas to the right of the superior mesenteric vein.
Randomization and inclusion
Randomisation will be performed with computer-generated random numbers in block of 10 (5:5). The randomisation is done by a research nurse that does not participate in the patient care. Study group allocation will depend upon the contents of sealed opaque envelopes generated in this manner, opened after the patient inclusion. Written and oral information about the study will be given by surgeon at the outpatient clinic and if the patient accepts to participate this is followed by signing of a written informed consent
Treatment
LDP (treatment group)
In general anaesthesia with the patient in the supine position 4 trocars are placed; above the umbilicus (12 mm), in the lateral part of the left rectus abdominis muscle (12 mm), to the left of the xiphoid process (5 mm) and in the left flank (5 mm). The surgeon and assisting surgeon (controlling the camera) stand on the patients right side.
The left colonic flexure is mobilized and the splenocolic ligament divided. Thereafter, the omental bursa is opened and the stomach completely mobilized, including the short gastric vessels. The lesion in the pancreas is identified with or without the help of ultrasonography. The inferior border of the pancreas is dissected and if found appropriate a band is placed around the pancreas between the lesion and the spleen. To the right of the lesion a band is placed around the pancreas (and the splenic vein if splenectomy is intended). Before dividing the pancreas the splenic artery is identified and secured with Hem-o-lock clips (Teleflex Medical, Weck Drive, Research Triangle Park, NC, USA). In case of spleen preserving procedure, the splenic artery is dissected from the pancreas and left intact. In order to improve visibility of the superior border of the pancreas the stomach is sutured to the anterior abdominal wall. Depending on the preoperative assessment lymphadenectomy is performed as indicated for pancreatic adenocarcinoma. The pancreas is divided using linear stapler with cartridge size based on the thickness of the pancreas. A slow compression and division is applied in order to reduce risk of rupture of the pancreas along the stapling line. Following division of the pancreas the resection is carried out in a medial to lateral direction. The surgical specimen is placed in a plastic bag and retrieved through enlargement of the trocar incision above the umbilicus. A 24 Ch passive drain is placed through the trocar incision in the left flank with the tip in front of the pancreatic transection line.
ODP (control group)
After a midline laparotomy and placement of retractors the resection is carried out essentially as described above. The stomach is retracted with retractor instead of sutures and the splenic artery is suture ligated instead of the use of clips. No attempt is made to dissect around the pancreas between the lesion and the spleen as antegrade resection is applied. The division of the pancreas is performed in the same manner as in the LDP group and drain is placed in the same way. Lymphadenectomy is performed when indicated.
Conversion to open surgery
Conversion (in the LDP group) is defined as any incision that is not for trocar placement or surgical specimen retrieval. In case of conversion, analysis will be done in an intention-to-treat manner.
Postoperative treatment
Both groups follow a fast track program omitting the use of nasogastric tube directly after operation (in the operating theatre) and encouraging oral intake as soon as possible. Epidural anaesthesia is allowed in the ODP group but not applied in the LDP group.
Study outcomes
The primary outcome variable of the LAPOP study is hospital stay defined as the number of days spent in the hospital after surgery. The study hypothesis is that LDP results in shorter hospital stay than ODP.
Secondary outcomes include functional recovery (key secondary outcome) defined as the number of days needed to reach no need for intravenous drug administration or fluids as well ambulatory patient able to perform ADL. This does not exclude discharge with drains or urinary catheters. Other secondary outcomes are perioperative bleeding (assessment done by anesthesia nurse), use of pain medications, complications (according to Clavien Dindo classification), the frequency of postoperative pancreatic fistula, quality of life and, lymph node harvesting, R0 frequency and cost.
Follow up and data collection
Baseline characteristics are collected in standardized case report forms (CRF) before randomization. Data for the outcome variables is collected in separate CRF for surgical procedure, hospital stay, pathology report and 90 day follow up. In addition, quality of life is assessed with EORTC QLQ-C30 to which is added the PAN26 module and EQ-5D.
The questionnaires will be filled out by the study subjects at inclusion, after 4-6 weeks from surgery, at 6,12 and 24 months postoperatively. Patients not returning questionnaires will be contacted by research nurse in order to improve follow up. Survival will be followed up to 24 months postoperatively (Figure 2).
Statstical analysis
The analyses will be based on the intention to treat principle. Primary outcome and key secondary outcome will be tested with t-test. Demography, treatment and clinical data will be reported.
Quality of life as measured by the EORTC QLQ-C30, EORTC PAN26 and EQ-5D will be analysed.
Cost-benefit analysis will be performed with regards to the operation, postoperative complications and interventions, days in hospital, need for postoperative outpatient treatment, readmissions for complications, tumor recurrence. Cost for sick leave will be included.
The study is done without Data monitoring committee (DMC) and no interim analysis is planned.